Durvalumab + Tremelimumab

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 39/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Intrahepatic Cholangiocarcinoma

Conditions

Intrahepatic Cholangiocarcinoma

Trial Timeline

Nov 1, 2019 → Dec 1, 2027

NCT ID

NCT04238637

About Durvalumab + Tremelimumab

Durvalumab + Tremelimumab is a phase 2 stage product being developed by AstraZeneca for Intrahepatic Cholangiocarcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT04238637. Target conditions include Intrahepatic Cholangiocarcinoma.

What happened to similar drugs?

0 of 4 similar drugs in Intrahepatic Cholangiocarcinoma were approved

Approved (0) Terminated (1) Active (3)

🔄A4250 (odevixibat)IpsenPhase 3

🔄MaralixibatMirum PharmaceuticalsPhase 3

❌Maralixibat + PlaceboMirum PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05345678	Pre-clinical	Completed	—	—	Unresectable Hepatocellular Carcinoma
NCT07081633	Phase 2	Recruiting	Aug 5, 2025	Dec 31, 2028	Hepatocellular Carcinoma
NCT05883644	Phase 3	Active	Jun 27, 2023	Sep 30, 2026	Advanced Hepatocellular Carcinoma
NCT05701488	Phase 1	Recruiting	Apr 21, 2023	Oct 1, 2026	Resectable Hepatocellular Carcinoma
NCT05557838	Phase 3	Recruiting	Feb 22, 2023	Mar 31, 2025	Hepatocellular Carcinoma
NCT04430452	Phase 2	Recruiting	Feb 4, 2022	Jul 31, 2029	Advanced Hepatocellular Carcinoma
NCT05000710	Phase 2	Active	Dec 9, 2021	Dec 1, 2026	Metastatic or Locally Advanced NSCLC
NCT04499053	Phase 2	Recruiting	Dec 9, 2020	Dec 1, 2027	Carcinoma, Non-Small Cell Lung
NCT04395079	Phase 2	Active	Aug 7, 2020	Dec 1, 2026	Metastatic Malignant Female Reproductive System Neoplasm
NCT04238637	Phase 2	Active	Nov 1, 2019	Dec 1, 2027	Intrahepatic Cholangiocarcinoma
NCT03638141	Phase 2	Completed	Oct 2, 2019	Aug 20, 2024	Intermediate Stage of Hepatocellular Carcinoma
NCT03702179	Phase 2	Completed	Nov 19, 2018	Aug 16, 2022	Invasive Bladder Cancer
NCT03704480	Phase 2	Active	Nov 9, 2018	Dec 31, 2025	Advanced Biliary Tract Carcinoma
NCT03601455	Phase 2	Active	Oct 26, 2018	Jan 31, 2027	Bladder Urothelial Carcinoma
NCT03618134	Phase 1/2	Terminated	Oct 4, 2018	Jun 30, 2023	Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8
NCT03703297	Phase 3	Active	Sep 27, 2018	Oct 23, 2026	Small Cell Lung Cancer
NCT03624231	Phase 2	Completed	Aug 15, 2018	Aug 17, 2023	Squamous Cell Carcinoma of the Head and Neck
NCT03288532	Phase 3	Recruiting	Jul 19, 2018	Dec 1, 2034	Renal Cell Carcinoma
NCT03283605	Phase 1/2	Active	Jul 17, 2018	Dec 31, 2024	Head and Neck Squamous Cell Carcinoma
NCT03277482	Phase 1	Terminated	Jun 1, 2018	Jul 15, 2022	Recurrent Gynecological Cancer

Competing Products

20 competing products in Intrahepatic Cholangiocarcinoma

See all competitors

Product	Company	Stage	Hype Score
Apatinib	Jiangsu Hengrui Medicine	Phase 2	31
Apatinib and Adebrelimab in Combination With chemotherapy	Jiangsu Hengrui Medicine	Phase 2	42
Apatinib	Jiangsu Hengrui Medicine	Phase 2	35
Famitinib	Jiangsu Hengrui Medicine	Phase 2	27
Camrelizumab + Apatinib	Jiangsu Hengrui Medicine	Phase 2	31
Durvalumab + SNDX-6352	AstraZeneca	Phase 2	35
Pemigatinib + Durvalumab	AstraZeneca	Phase 2	42
Durvalumab + Gemcitabine + Cisplatin	AstraZeneca	Phase 2	42
Pemigatinib	Incyte	Phase 2	24
A4250 (odevixibat)	Ipsen	Phase 3	37
Odevixibat	Ipsen	Pre-clinical	23
CGT4859	Cogent Biosciences	Phase 1/2	36
LUM001 (Maralixibat)	Mirum Pharmaceuticals	Phase 2	32
Maralixibat	Mirum Pharmaceuticals	Phase 3	37
Maralixibat	Mirum Pharmaceuticals	Phase 2	39
Maralixibat	Mirum Pharmaceuticals	Phase 2	32
Volixibat + Placebo	Mirum Pharmaceuticals	Phase 2	24
Maralixibat	Mirum Pharmaceuticals	Phase 3	37
Maralixibat + Placebo	Mirum Pharmaceuticals	Phase 3	29
HMPL-453 + Rabeprazole	HUTCHMED	Phase 1	23